title: Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.
abstract: Toxicities resulting from platinum based chemotherapy in head and neck cancer is a cause for much concern. There is a lack of clinical criteria for defining these patient populations, which has posed serious problems associated with increased morbidity and consequently an adverse effect on patients' quality of life. In addition, there is a lack of consensus on clinical criteria for defining such patient populations, who may be unsuitable for concurrent chemoradiotherapy. A group of experts in the field of head and neck cancer from the Asia Pacific Region convened in August 2014 in Korea to discuss the development of a set of clinical criteria in order to fill the knowledge gap and provide a reference tool for head and neck oncologists. This paper reports the final output from this meeting and the accompanying literature review, with the aim of aiding clinical decision making with the help of some clinical criteria to identify platinum unsuitable patient populations in head and neck cancer management. Some alternative treatment options are also discussed in this paper.
authors.affiliation: Samsung Medical Center, Seoul, Republic of Korea.
authors.forename: Myung-Ju
authors.initials: MJ
authors.lastname: Ahn
authors.affiliation: Tata Memorial Hospital, Mumbai, India.
authors.forename: Anil
authors.initials: A
authors.lastname: D'Cruz
authors.affiliation: University Hospital Antwerp, Edegem, Belgium.
authors.forename: Jan B
authors.initials: JB
authors.lastname: Vermorken
authors.affiliation: National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Jo-Pai
authors.initials: JP
authors.lastname: Chen
authors.affiliation: Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand.
authors.forename: Imjai
authors.initials: I
authors.lastname: Chitapanarux
authors.affiliation: Ho Chi Minh City Oncology Hospital, Ho Chi Minh City, Viet Nam.
authors.forename: Huy Quoc Thinh
authors.initials: HQ
authors.lastname: Dang
authors.affiliation: Royal North Shore Hospital, Sydney, Australia.
authors.forename: Alex
authors.initials: A
authors.lastname: Guminski
authors.affiliation: King Chulalongkorn University Hospital, Bangkok, Thailand.
authors.forename: Danita
authors.initials: D
authors.lastname: Kannarunimit
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
authors.affiliation: Pamela Youde Nethersole Eastern Hospital, Hong Kong.
authors.forename: Wai Tong
authors.initials: WT
authors.lastname: Ng
authors.affiliation: Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.
authors.forename: Keon-Uk
authors.initials: KU
authors.lastname: Park
authors.affiliation: Chinese University of Hong Kong, Hong Kong. Electronic address: anthonytcchan@cuhk.edu.hk.
authors.forename: Anthony Tak Cheung
authors.initials: AT
authors.lastname: Chan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001208:Asia; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects* / Q000379:methods; D002945:Cisplatin / Q000009:adverse effects*; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
keywords: Chemoradiotherapy; Cisplatin; Criteria; Expert opinion; Head and neck cancer; Patients; Toxicity; Unsuitability